Avtor/Urednik		Boltežar, Lučka; Poglajen, Gregor
Naslov		Srčno popuščanje in onkološko zdravljenje
Prevedeni naslov		Heart failure and oncologic treatment
Tip		članek
Vol. in št.		Letnik 89, št. 7/8
Leto izdaje		2020
Obseg		str. 432-445
ISSN		1318-0347 - Zdravniški vestnik : glasilo Slovenskega zdravniškega društva : Slovenian medical journal
Jezik		slv
Abstrakt		Heart failure after oncological treatment is a hot topic in oncology as well as in cardiology and it demands quick diagnostic and therapeutic interventions. The most commonly used classification of myocardial damage is still type I (anthracycline-like) and type II (trastuzumab-like) myocardial injury. Radiotherapy is also a significant contributor to cardiotoxicity in oncologic patients. The European Society of Cardiology has published guidelines regarding surveillance and follow up of such patients, the golden standard of imaging techniques being echocardiography. Other imaging techniques and laboratory modalities could be used but are not widely available. This year's recommendations of the European Society of Medical Oncology advise considering the use of cardioprotective medications before and during therapy in individuals with known cardiovascular risk factors. However, individual approach to every patient is of paramount importance.
Proste vsebinske oznake		poškodba miokarda antraciklini reprečevanje srčnega popuščanja myocard injury anthracyclins heart failure prevention